Moderna (MRNA) flu vaccine mRNA-1010 shows positive Phase 3 data
Moderna shares closed up 4.3% on 30 April 2026, ending the session at $47.70. The move followed positive Phase 3 data for the company's mRNA-1010 trivalent flu vaccine, later published in the New England Journal of Medicine on 6 May 2026.
The trial data indicated a 26.6% relative vaccine efficacy against standard shots. Regulatory submissions for the mRNA-1010 vaccine are currently under review in the United States, European Union, Canada, and Australia, with approvals anticipated for 2026.
Further supporting the stock's performance, Moderna reached a $950,000,000 litigation settlement with Arbutus and Genevant, removing associated royalty risks. Analyst firm Brookline subsequently raised its FY2026 EPS estimates, citing the flu vaccine's upside potential.
Why positive flu vaccine data boosted Moderna's outlook
Moderna is a biotechnology company focused on developing messenger RNA (mRNA) based medicines and vaccines. Their core activity involves designing synthetic mRNA sequences that instruct the body's cells to produce specific proteins, which can then fight diseases or generate an immune response. They primarily serve patients and healthcare providers by offering innovative treatments for various conditions, with their revenue generated from the sale of these advanced therapeutic products.
The primary driver behind Moderna's share price increase was the release of positive Phase 3 clinical trial data for its mRNA-1010 trivalent flu vaccine. This crucial data, later published in the New England Journal of Medicine, indicated a significant 26.6% relative vaccine efficacy against standard shots. This successful trial moves the vaccine closer to market approval, de-risking a major future revenue stream for the company, while a $950,000,000 litigation settlement also removed associated royalty risks.
This encouraging news saw Moderna's shares close up 4.3%, ending the session on 30 April 2026 at $47.70, up from its previous close of $45.72.
Think of it like a chef perfecting a brand-new, complex recipe. After months of development, they finally get a unanimous thumbs-up from a panel of expert tasters, confirming it's not just good, but significantly better than existing options. That positive feedback doesn't just mean a great meal, it signals that this new dish is ready for the menu, likely to attract many customers, and will contribute meaningfully to the restaurant's future success.
Moderna
Moderna, Inc. (MRNA) is a biotechnology firm focused on developing and commercialising messenger RNA (mRNA) therapeutics and vaccines. Its extensive pipeline addresses infectious diseases, immuno-oncology, rare conditions, cardiovascular ailments, and autoimmune disorders across the United States, Europe, and other international markets. Key vaccine programmes target respiratory illnesses, including COVID-19 and flu, alongside latent viruses such as cytomegalovirus and herpes simplex virus, and public health threats like Zika. The company also develops cancer vaccines, systemic and intratumoral immuno-oncology products, and regenerative therapeutics. Moderna engages in strategic alliances with partners including AstraZeneca PLC, Merck & Co., Inc., and Vertex Pharmaceuticals Incorporated. Founded in 2010, Moderna, Inc. is headquartered in Cambridge, Massachusetts.